Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Trevena, Inc. (TRVN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7363-0.0564 (-7.11%)
At close: 4:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.7927
Open0.7856
Bid0.7400 x 900
Ask0.7500 x 800
Day's Range0.7300 - 0.7979
52 Week Range0.6510 - 3.1000
Volume1,891,428
Avg. Volume1,363,860
Market Cap120.454M
Beta (5Y Monthly)2.45
PE Ratio (TTM)N/A
EPS (TTM)-0.2330
Earnings DateNov 01, 2021 - Nov 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.33
  • Zacks

    Trevena (TRVN) Reports Q3 Loss, Lags Revenue Estimates

    Trevena (TRVN) delivered earnings and revenue surprises of 11.11% and -84.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Trevena Reports Third Quarter 2021 Results

    -- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected to start in Q1 2022 Initiated enrollment for Cleveland Clinic-led OLINVYK outcomes study, topline data expected in mid-2022 Progressed TRV027 with NIH / ACTIV-4 trial for COVID-19 on track for topline data in mid-2022 $78.6M cash at Q3 funds operations through YE 2022 -- Company to host conference call today, Nove

  • GlobeNewswire

    Trevena Adds Seasoned Biopharma Commercial Executive to Senior Leadership Team

    Patricia Drake appointed new Chief Commercial OfficerCHESTERBROOK, Pa., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the addition of Patricia Drake to its senior leadership team as Chief Commercial Officer. ‘I am thrilled to have Pattie join our executive team and help us bring OLINVYK to the next level,” said

Advertisement
Advertisement